90 related articles for article (PubMed ID: 29663420)
1. Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection.
German P; Xin Y; Chien JW; Weng W; Mackman R; Lewis SA; Meng A; Ling J; Mathias A
J Clin Pharmacol; 2018 Aug; 58(8):1025-1034. PubMed ID: 29663420
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.
Marty FM; Chemaly RF; Mullane KM; Lee DG; Hirsch HH; Small CB; Bergeron A; Shoham S; Ljungman P; Waghmare A; Blanchard E; Kim YJ; McKevitt M; Porter DP; Jordan R; Guo Y; German P; Boeckh M; Watkins TR; Chien JW; Dadwal SS
Clin Infect Dis; 2020 Dec; 71(11):2787-2795. PubMed ID: 31915807
[TBL] [Abstract][Full Text] [Related]
3. Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.
Stray K; Perron M; Porter DP; Anderson F; Lewis SA; Perry J; Miller M; Cihlar T; DeVincenzo J; Chien JW; Jordan R
J Infect Dis; 2020 Oct; 222(9):1468-1477. PubMed ID: 31971597
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.
Chemaly RF; Dadwal SS; Bergeron A; Ljungman P; Kim YJ; Cheng GS; Pipavath SN; Limaye AP; Blanchard E; Winston DJ; Stiff PJ; Zuckerman T; Lachance S; Rahav G; Small CB; Mullane KM; Patron RL; Lee DG; Hirsch HH; Waghmare A; McKevitt M; Jordan R; Guo Y; German P; Porter DP; Gossage DL; Watkins TR; Marty FM; Chien JW; Boeckh M
Clin Infect Dis; 2020 Dec; 71(11):2777-2786. PubMed ID: 31793991
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant.
Gottlieb J; Torres F; Haddad T; Dhillon G; Dilling DF; Knoop C; Rampolla R; Walia R; Ahya V; Kessler R; Budev M; Neurohr C; Glanville AR; Jordan R; Porter D; McKevitt M; German P; Guo Y; Chien JW; Watkins TR; Zamora MR
J Heart Lung Transplant; 2023 Jul; 42(7):908-916. PubMed ID: 36964084
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus.
Porter DP; Guo Y; Perry J; Gossage DL; Watkins TR; Chien JW; Jordan R
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32071058
[TBL] [Abstract][Full Text] [Related]
7. The Drug-Drug Interaction Profile of Presatovir.
Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
[TBL] [Abstract][Full Text] [Related]
8. Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Oey A; McClure M; Symons JA; Chanda S; Fry J; Smith PF; Luciani K; Fayon M; Chokephaibulkit K; Uppala R; Bernatoniene J; Furuno K; Stanley T; Huntjens D; Witek J;
PLoS One; 2023; 18(7):e0288271. PubMed ID: 37467213
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors.
Yamaguchi-Sasaki T; Tamura Y; Ogata Y; Kawaguchi T; Kurosaka J; Sugaya Y; Iwakiri K; Busujima T; Takahashi R; Ueda-Yonemoto N; Tanigawa E; Abe-Kumasaka T; Sugiyama H; Kanuma K
Chem Pharm Bull (Tokyo); 2020; 68(4):345-362. PubMed ID: 32238652
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP
Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
[TBL] [Abstract][Full Text] [Related]
12. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.
Meissner HC; Groothuis JR; Rodriguez WJ; Welliver RC; Hogg G; Gray PH; Loh R; Simoes EA; Sly P; Miller AK; Nichols AI; Jorkasky DK; Everitt DE; Thompson KA
Antimicrob Agents Chemother; 1999 May; 43(5):1183-8. PubMed ID: 10223933
[TBL] [Abstract][Full Text] [Related]
14. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
16. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
Mackman RL; Sangi M; Sperandio D; Parrish JP; Eisenberg E; Perron M; Hui H; Zhang L; Siegel D; Yang H; Saunders O; Boojamra C; Lee G; Samuel D; Babaoglu K; Carey A; Gilbert BE; Piedra PA; Strickley R; Iwata Q; Hayes J; Stray K; Kinkade A; Theodore D; Jordan R; Desai M; Cihlar T
J Med Chem; 2015 Feb; 58(4):1630-43. PubMed ID: 25574686
[TBL] [Abstract][Full Text] [Related]
17. Oral GS-5806 activity in a respiratory syncytial virus challenge study.
DeVincenzo JP; Whitley RJ; Mackman RL; Scaglioni-Weinlich C; Harrison L; Farrell E; McBride S; Lambkin-Williams R; Jordan R; Xin Y; Ramanathan S; O'Riordan T; Lewis SA; Li X; Toback SL; Lin SL; Chien JW
N Engl J Med; 2014 Aug; 371(8):711-22. PubMed ID: 25140957
[TBL] [Abstract][Full Text] [Related]
18. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.
Jordan R; Shao M; Mackman RL; Perron M; Cihlar T; Lewis SA; Eisenberg EJ; Carey A; Strickley RG; Chien JW; Anderson ML; McEligot HA; Behrens NE; Gershwin LJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4889-900. PubMed ID: 26055364
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
